Date : 18 May 2026

| Companies | Headquarters | Veterinary Regenerative Medicines |
| Zoetis Inc. | Parsippany, U.S. | Pro-stride APS and Restigen PRP |
| Vetherapy | Miami, U.S. | Hypo-Stem |
| VetStem, Inc. | Poway, U.S. | VetStem Cell Therapy and Steminsure |
| Animal Cell Therapies | San Diego, U.S. | ACT Canine Stem Cell Therapy |
| Boehringer Ingelheim | Ingelheim, Germany | Arti-Cell Forte and RenuTend |
| Vetbiologics | Olean, U.S. | V-Pet and BMAC kits |
| Dechra Pharmaceuticals | Northwich, UK | Orthokine vet irap and Osteokine PRP |
| Medrego | Riga, Latvia | CaniCell and EquiCell |
| Ardent Animal Health | Lexington, U.S. | Ardent Stem Cell Therapy and PurePRP |
| Enso Discoveries | Manhattan, U.S. | Rebound PRP and Rebond PRF |
R&D
Clinical Trials and Regulatory Approvals
Patient Support and Services
The global veterinary regenerative medicine market size was estimated at USD 1.42 billion in 2025 and is predicted to increase from USD 1.6 billion in 2026 to approximately USD 4.74 billion by 2035, expanding at a CAGR of 12.8% from 2026 to 2035.

Speak with a healthcare analyst about your research, consulting, or platform needs.